China Health Resource (CHRI) CEO Delivers Speech to the 17th People’s Congress of Pingwu, Sichuan
SHANGHAI, Jan. 12, 2012 /PRNewswire-Asia-FirstCall/ — Jiayin Wang, Chairman and CEO of China Health Resource, Inc. (OTCBB: CHRI.OB News), announced today he has been elected as representative member to the 17th People’s Congress of Pingwu County in Sichuan, People’s Republic of China where he delivered a speech to Congress.
Jiayin Wang’s speech was focused on the strategic goals the government should adopt in order to support and encourage businesses to make herbal medicines using GAP standards and creating rich quality brands. “So that herbal healthcare products out of China can benefit the world and also reward those who make investment in this area,” says Mr. Jiayin Wang during his speech to the People’s Congress.
Jiayin Wang has been the People’s Senator of Suining City, Sichuan Province, People’s Republic of China (“PRC”) since 1995. He has been 12 consecutive time recipient for the national award in the People’s Republic of China. In 2006, he received the China’s 500 Great Entrepreneurs Award given by the President of the People’s Republic of China. Wang has served as President and Chairman of the Board of Directors of Sichuan Yinfa Resource Development Co., Ltd., an affiliate of CHRI, where he spearheaded the development of the standardization of pharmaceutical grade Dahurian Angelica Root (DAR) under the Chinese State Food and Drug Administration Good Agricultural Practice (GAP) of Medical Plants and Animals. Additionally, he has been the Chairman of Sichuan Province DAR Association since 2001.
China Health Resource , Inc. (CHRI) is the leading provider of GAP quality DAR in the People’s Republic of China (PRC) under the registered Trademark Chuan Baizhi(TM) The company strives at modernizing Traditional Chinese Medicine (TCM) and is now extending its GAP DAR know-how to other TCM herbs.
CHRI, who successfully pioneered and commercialized GAP Dahurian Angelica Root (DAR), is providing its expertise in implementing General Agricultural Practices (GAP) to Gastrodia.
“Gastrodia is considered one of the higher valued herbs in TCM, currently retailing for about 250~1,000 yuan/kg (US$38~150/kg). Pingwu Gastrodia is known for its high purity and efficacy. Our objective at CHRI is to commercialize Gastrodia in the most pure form and using GAP standards as we did with GAP DAR. Unlike other herbs, Gastrodia is a tuber that grows best under clean environmental conditions, free from pollutants, and most importantly within given altitude,” said Yi Peng, Deputy General Manager, who has been involved in GAP implementation starting with GAP DAR.
China Health Resource, Inc. engages in the development, manufacturing, processing, marketing and sale of raw and pharmaceutical TCM products including Dahurian Angelica Root (DAR) and Rhizoma Gastrodiae and is only the provider of GAP quality DAR in the People’s Republic of China under the registered Trademark Chuan Baizhi(TM). DAR, which is also known as “Bai Zhi” in Mandarin Chinese, is an herb that is employed as an ingredient in medicine, cosmetics and food, as well as used in TCM for the treatment of pain, swelling and pustule. The Company’s DAR-related products include the Bailing Capsule, Yisheng Capsule, Kimchee-Mate and Fragrant Bag, all of which are sold through regional distributors. The Company was founded in 2001 and is based in Suining, Sichuan Province. More information may be found at the corporate website at www.chinahealthresource.com.
Certain statements in this document regarding financial matters, other than historical facts, and statements of our expectations, intentions, plans and beliefs, constitute “forward-looking statements” within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to certain events, risks and uncertainties that may be outside our control. The words “believe”, “expect”, “anticipate”, “optimistic”, “intend”, “will”, and similar expressions identify forward-looking statements. The company intends that such proclamations about future expectations, including future revenues and earnings, future business expansion plans, and all other forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company’s actual results may differ materially from expected results. These and other risks and uncertainties related to our business are described in greater detail in our filings with the Commission. The foregoing information should be read in conjunction with these filings. We disclaim any intention or obligation to update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made.
SOURCE China Health Resource